Safety and Efficacy of Anti-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM

NCT05749133 | Unknown Phase 1

• 1 other identifier: BG-CT-22-011
• Study Type: interventional
• Target: 18
• Locations: 1 country
• Sites: 1

Brief Summary

It is a single-center, open-labeled, single-arm, non-randomized investigatorinitiated trial evaluating the efficacy and safety of anti-GPRC5D CAR-T cells therapy for relapsed and refractory(r/r) multiple myeloma(MM) after three or more lines of treatments.

Conditions

Multiple Myeloma in Relapse; Multiple Myeloma, Refractory

Keywords

CAR-T

Outcome Measures

Primary Outcomes (6)

• Incidence of adverse events(AE) after infusion

  The frequency, severity, and laboratory findings of all adverse events/serious adverse events are included. Description, time, classification, and outcome of AE events resulted from the investigational medical product, delivery method, or emergency measures will be recorded in the case report form.

  Up to the subject withdrew or 24 months after CAR-T infusion.

• Dose limited toxicity (DLT)

  Dose limited toxicity(DLT) was defined as the occurrence of any of the following adverse events within 28 days of the infusion of CAR-T cells after optimal supportive treatment, which were discussed with the investigator and determined to be associated or likely to be associated with the infusion.

  Up to 28 days after infusion.

• Overall response rate(ORR)

  Overall Response Rate (ORR) is defined as the proportion of subjects achieving strict complete remission(sCR), complete response(CR), very good partial response(VGPR) and partial response(PR).

  Day 28 and months 3, 6, 9, 12, 18, 24 after CAR-T infusion.

• Clinical benefit rate

  It's defined as the sum of the proportion of subjects who achieved ORR (sCR + CR + VGPR + PR) and minimal response (MR) according to the International Myeloma Working Group (IMWG) criteria.

  Day 28 and months 3, 6, 9, 12, 18, 24 after CAR-T infusion.

• Progression-free survival(PFS)

  Progression-free survival(PFS) refers to the time from cell reinfusion to the first assessment of tumor progression or death from any cause.

  Up to 24 months after CAR-T infusion.

• Overall survival(OS)

  Overall survival (OS) refers to the time from the time the patient received an infusion of CAR-T cells until death (from any cause).

  Up to 24 months after CAR-T infusion.

Secondary Outcomes (2)

• Concentration of CAR-T cells

  Up to 3 months after CAR-T infusion.

• Concentration of cytokine

  Up to 28 days after CAR-T infusion.

Study Arms (1)

Anti-GPRC5D CAR-T

EXPERIMENTAL

Subjects who meet the enrollment conditions will receive intravenous infusion of Anti-GPRC5D CAR-T Cells Injection, doses of 1.0\~6.0×10\^6 /kg±20% CAR-T cells, after lymphodepleting therapy.

Biological: Anti-GPRC5D CAR-T Cells Injection

Interventions

Anti-GPRC5D CAR-T Cells Injection BIOLOGICAL

This is a"3+3"dose escalation study, in which three dose groups are set three different dose levels of CAR-T cells: Initial dose group: 3.0×10\^6/kg±20%; Low dose group: 3.0×10\^6/kg±20%; High dose group: 6.0×10\^6/kg±20%. Dose was weight-based.

Anti-GPRC5D CAR-T

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• The patient understands and voluntarily signs the informed consent, and is expected to complete the follow-up examination and treatment of the study procedure.
• Age 18 to 75 years old, gender is not limited.
• Diagnosed with multiple myeloma according to IMWG diagnostic criteria.
• Have received third-line or above treatment.
• Have measurable lesions at screening period, defined as any of the following : (1) serum monoclonal immunoglobulin (M-protein) level ≥1.0 g/dL. (2) urine M protein level ≥200 mg/ 24h. (3) Light chain multiple myeloma diagnosed with no measurable lesion in serum or urine: serum immunoglobulin free light chain is ≥10 mg/dL and serum immunoglobulin κ/γ free light chain ratio is abnormal.
• The patient has recovered from the toxicity of the previous treatment, that is, the CTCAE toxicity grade is less than 2 (unless the abnormality is related to the tumor or is in a stable state as judged by the investigator, which has little effect on safety or efficacy).
• Eastern cooperative oncology group (ECOG) score is 0-2, and survival is expected to be greater than 3 months.
• Has proper organ function: (1) Alanine aminotransferase (ALT) ≤3 times the upper limit of normal (ULN). (2) Aspartate aminotransferase (AST) ≤3 times ULN. (3) Total bilirubin ≤1.5 ULN. (4) Serum creatinine ≤1.5 ULN, or creatinine clearance ≥60 mL/min. (5) Indoor oxygen saturation ≥92%. (6) Left ventricular ejection fraction (LVEF) ≥45%, echocardiography confirmed no pericardial effusion, no ECG findings with clinical sense. (6) There was no clinically significant pleural effusion.
• The venous access required for collection can be established, and there are no contraindications to leukocyte collection.

You may not qualify if:

• Have been diagnosed with or treated for aggressive malignancies other than multiple myeloma within 3 years.
• Subjects who have received the following therapies before blood collection: have received targeted therapy, epigenetic therapy, or investigational drug therapy or invasive investigational medical device within 14 days or at least five half-lives, whichever is shorter, or have treated with monoclonal antibodies within 21 days, or have received cytotoxic therapy within 14 days, or have treated with a proteasome inhibitor within 14 days, or have treated with an immunomodulatory agent within 7 days, or have received radiotherapy within 14 days (except bone marrow reserve with field coverage ≤ 5%).
• It is suspected that MM has involved the central nervous system or meninges and has been confirmed by MRI or CT, or there are other active central nervous system diseases.
• Patients with macroglobulinemia, POEMS syndrome (polyneuropathy, organ enlargement, endocrine disease, monoclonal proteinosis, and skin changes) or primary AL amyloidosis at the time of screening.
• Hepatitis B surface antigen (HBsAg) is positive, or Hepatitis B core antibody (HBcAb) positive while HBV DNA titer in peripheral blood higher than the lower limit of detection. Hepatitis C virus (HCV) antibody positive and the peripheral blood HCV RNA also positive. Human immunodeficiency virus (HIV) antibody positive. Cytomegalovirus (CMV) DNA test results ≥500 copies /mL. Syphilis test positive.
• Those with a history of severe allergies or known any of the active ingredients, excipients or mouse-derived products contained in the drug, or those allergic to xenogeneic proteins in this trial, including lymphocyte depletion regimens. Severe allergy history is defined as an allergic reaction of grade two or above, and any of the following clinical manifestations occur when an allergic reaction occurs: airway obstruction (runny nose, cough, wheezing, dyspnea), hypercardia tachycardia, hypotension, arrhythmia, gastrointestinal symptoms (nausea, vomiting), incontinence, laryngeal edema, bronchospasm, cyanosis, shock, respiration, cardiac arrest.
• Severe heart disease, including but not limited to severe arrhythmia, unstable angina, massive myocardial infarction, New York Heart Association class III or IV cardiac insufficiency, refractory hypertension (refractory Hypertension is defined as: on the basis of improving lifestyle, a reasonable tolerable and sufficient amount of ≥3 kinds of antihypertensive drugs (including diuretics) has been used for \> 1 month and the blood pressure has not reached the standard, or the blood pressure can only be achieved effective control after taking ≥4 kinds of antihypertensive drugs.
• Systemic diseases judged by investigators to be unstable, including but not limited to severe liver, kidney or metabolic diseases requiring drug treatment.
• Patients with acute/chronic graft-versus-host disease (GVHD) within 6 months prior to screening, or requiring immunosuppressive therapy for GVHD.
• Active autoimmune or inflammatory diseases of the nervous system (eg, Guillain-Barre syndrome (GBS), amyotrophic lateral sclerosis (ALS)) and clinically significant active cerebrovascular disease (eg, cerebral edema) , Posterior Reversible Encephalopathy Syndrome (PRES)).
• Those who have tumor emergencies (such as spinal cord compression, intestinal obstruction, leukostasis, tumor lysis syndrome, etc.) before screening or reinfusion and need emergency treatment.
• The presence of an uncontrolled bacterial, fungal, viral or other infection requiring antibiotic treatment.
• Those who have undergone major surgical operations (except diagnostic surgery and biopsy) within 4 weeks before clearing the lymph cells, or those who plan to undergo major surgery during the study period, or those whose surgical wounds have not healed completely before enrollment.
• Those who have received (attenuated) live virus vaccine within 4 weeks before screening.
• Persons with severe mental illness.

Sponsors & Collaborators

• XuYan: lead

Study Sites (1)

Institute of Hematology & Blood Diseases Hospital

Tianjin, China

RECRUITING

MeSH Terms

Conditions

Multiple Myeloma

Condition Hierarchy (Ancestors)

Neoplasms, Plasma Cell; Neoplasms by Histologic Type; Neoplasms; Hemostatic Disorders; Vascular Diseases; Cardiovascular Diseases; Paraproteinemias; Blood Protein Disorders; Hematologic Diseases; Hemic and Lymphatic Diseases; Hemorrhagic Disorders; Lymphoproliferative Disorders; Immunoproliferative Disorders; Immune System Diseases

Study Officials

• Yan Xu, MD

  Institute of Hematology & Blood Diseases Hospital, China

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Yan Xu, MD

CONTACT

13920593907; xuyan1@ihcams.ac.cn

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Associate chief physician

Study Record Dates

• First Submitted: February 18, 2023
• First Posted: March 1, 2023
• Study Start: April 10, 2023
• Primary Completion: March 1, 2025
• Study Completion: December 1, 2025
• Last Updated: April 20, 2023

Record last verified: 2023-04

Locations

CN (1)